The overall reported frequency of undesirable effects was determined from clinical studies in 316 patients (132 patients with non-small cell lung cancer and 184 patients with breast cancer) who received the recommended regimen of vinorelbine (first three administrations at 60 mg/m2
/week followed by 80 mg/m2
Adverse reactions reported are listed as follows, by system organ and by frequency. Additional adverse reactions from Post Marketing experience have been added according to the MedDRA classification with the frequency Not known
The reactions were described using the NCI common toxicity criteria: See Table 3.
Click on icon to see table/diagram/image
Reactions were described using the W.H.O. classification (grade 1=G1; grade 2=G2; grade 3=G3; grade 4=G4; grade 1-4=G1-4; grade 1-2=G1-2; grade 3-4=G3-4).
Adverse effects reported with Vinorelbine Soft-Gelatin Capsule:
Pre-marketing experience: The most commonly reported adverse drug reactions are bone marrow depression with neutropenia, anaemia and thrombocytopenia, gastrointestinal toxicity with nausea, vomiting, diarrhea, stomatitis and constipation. Fatigue and fever were also reported very commonly.
Post-marketing experience: Vinorelbine Soft-Gelatin Capsule is used as single agent or in combination with other chemotherapeutic or targeted therapy agents.
The most common system organ classes involved during post-marketing experience are: 'Blood and lymphatic system disorders', 'Gastrointestinal disorders', 'Infections and infestations' and 'General disorders and administration site conditions'. This information is consistent with the pre-marketing experience.
Infections and Infestations:
Very common: Bacterial, viral or fungal infections without neutropenia at different sites G1-4: 12.7%; G3-4: 4.4%.
Common: Bacterial, viral or fungal infections resulting from bone marrow depression and/or immune system compromise (neutropenic infections) are usually reversible with an appropriate treatment. Neutropenic infection G3-4: 3.5%.
Not known: Neutropenic sepsis.
Blood and lymphatic system disorders:
Very common: Bone marrow depression resulting mainly in neutropenia G1-4: 71.5%; G3: 21.8%; G4: 25.9%, is reversible and is the dose limiting toxicity. Leucopenia G1-4: 70.6%; G3: 24.7%; G4: 6%. Anemia G1-4: 67.4%; G3-4: 3.8%. Thrombocytopenia G1-2: 10.8%.
Common: G4 Neutropenia associated with fever over 38°C including febrile neutropenia: 2.8%.
Metabolism and nutrition disorders:
Not known: Severe hyponatraemia.
Common: Insomnia G1-2: 2.8%.
Nervous system disorders:
Very common: Neurosensory disorders G1-2: 11.1% were generally limited to loss of tendon reflexes and infrequently severe.
Common: Neuromotor disorders G1-4: 9.2%; G3-4: 1.3%. Headache: G1-4: 4.1%, G3-4: 0.6%. Dizziness: G1-4: 6%; G3-4: 0.6%. Taste disorders: G1-2: 3.8%.
Uncommon: Ataxia G3: 0.3%.
Common: Visual disorders G1-2: 1.3%.
Uncommon: Heart failure and cardiac dysrhythmia.
Not known: Myocardial infarction in patients with cardiac medical history or cardiac risk factors.
Common: Hypertension G1-4: 2.5%; G3-4: 0.3%. Hypotension G1-4: 2.2%; G3-4: 0.6%.
Respiratory system, thoracic and mediastinal disorders:
Common: Dyspnoea G1-4: 2.8%; G3-4: 0.3%. Cough G1-2: 2.8%.
Very Common: Nausea G1-4: 74.7%; G3-4: 7.3%. Vomiting G1-4: 54.7%; G 3-4: 6.3%; supportive treatment (such as oral setrons) may reduce the occurrence of nausea and vomiting. Diarrhoea G1-4: 49.7%; G3-4: 5.7%. Anorexia G1-4: 38.6%; G3-4: 4.1%. Stomatitis G1-4: 10.4%; G3-4: 0.9%. Abdominal pain: G1-4: 14.2%. Constipation G1-4: 19%; G3-4: 0.9%, Prescription of laxatives may be appropriate in patients with prior history of constipation and/or who received concomitant treatment with morphine or morphine-mimetics. Gastric disorders: G1-4: 11.7%.
Common: Oesophagitis G1-3: 3.8%; G3: 0.3%. Dysphagia: G1-2: 2.3%.
Uncommon: Paralytic ileus G3-4: 0.9% [exceptionally fatal] treatments may be resumed after recovery of normal bowel mobility.
Not Known: Gastrointestinal bleeding.
Common: Hepatic disorders: G1-2: 1.3%.
Skin and subcutaneous tissue disorders:
Very common: Alopecia usually mild in nature G1-2: 29.4% may occur.
Common: Skin reactions G1-2: 5.7%.
Musculoskeletal and connective tissue disorders:
Common: Arthralgia including jaw pain. Myalgia G1-4: 7%; G3-4: 0.3%.
Renal and urinary disorders:
Common: Dysuria G1-2: 1.6%. Other genitourinary disorders G1-2: 1.9%.
General disorders and administration site conditions:
Very common: Fatigue/malaise G1-4: 36.7%; G3-4: 8.5%. Fever G1-4: 13.0%; G3-4: 12.1%.
Common: Pain including pain at the tumour site G1-4: 3.8%; G3-4: 0.6%. Chills: G1-2: 1.3%.
Very common: Weight loss G1-4: 25%; G3-4: 0.3%.
Common: Weight gain G1-2: 1.3%.